In the current scenario, the Kidney/Renal Fibrosis Treatment market is an extremely beneficial commercial segment due to the growing number of patients suffering from various types CKD and renal fibrosis. Moreover, increasing government support for developing novel therapies and rising investment in R&D on developing personalized medicine in various private and the public hospital is further propelling the market growth. The advent of the promising drug in the market coupled with the increasing medical expenditure and growing medical tourism rate is another major factor pushing the market growth uphill. Additionally, various recent technological breakthroughs such as point-of-care drug delivery systems and penetration of personalized drug is likely to offer opportunity growth to the market over the forecast period.
As per Value Market Report, Kidney/Renal Fibrosis Market is expected to be worth USD 7.99 BN by 2030 with a CAGR of 5.29%.
ANGIOTENSIN-CONVERTING ENZYME (ACE) TO LEAD THE SEGMENT
The ACE inhibitor is dominating the segment owing to the rising application of various disorders such as heart, blood vessel, and kidney problems. Basically, this group of drugs causes relaxation of blood vessels as well as a decrease in blood volume, which resulted in lower blood pressure and decreased oxygen demand from the heart. They curb the growth of angiotensin-converting enzyme, an important component of the renin-angiotensin system. Henceforth, this segment is likely to grow on the ground of the rising prevalence of various renal disinfections along with the growing population base across the globe.
HOSPITAL TESTING TO GAIN THE TRACTION
The hospital testing accounted for the largest market in 2023. Hospital testing is leading the segment owing to the growing investment in R&D on developing personalized medicine in various private and the public hospital. Also, the rising number of the hospital along with growing healthcare expenditure is another major factor in boosting the growth of the segment.
NORTH AMERICA EMERGED AS THE LARGEST MARKET FOR KIDNEY FIBROSIS
North America is accounted for the largest market for kidney fibrosis treatment owing to the presence of a large base of patients suffering from chronic kidney disease (CKD). Major driving factors raising the growth of this market are the growing base of the population suffering from chronic kidney diseases and the high incidence rate of renal fibrosis among the population. Moreover, the development of safe and effective therapeutics for the treatment of kidney fibrosis is contributing to the growth of the regional market.
THIS REPORT INCLUDES KEY PLAYERS ALONG WITH THEIR MARKET SHARE
Galectin Therapeutics, Merck & Co., F. Hoffman-La Roche Ltd., Pfizer Inc., InterMune Inc., ProMetic Life-Sciences Inc., La Jolla Pharmaceutical Company, Genzyme Corporation, and BioLine Rx Ltd